Providing a diverse range of perspectives from bullish to bearish, 20 analysts have published ratings on Neurocrine Biosciences NBIX in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 9 | 7 | 0 | 0 |
| Last 30D | 0 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 3 | 0 | 0 |
| 2M Ago | 0 | 2 | 0 | 0 | 0 |
| 3M Ago | 4 | 6 | 4 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $161.9, with a high estimate of $219.00 and a low estimate of $114.00. This current average reflects an increase of 1.99% from the previous average price target of $158.74.
Decoding Analyst Ratings: A Detailed Look
An in-depth analysis of recent analyst actions unveils how financial experts perceive Neurocrine Biosciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Evan Seigerman | BMO Capital | Lowers | Market Perform | $114.00 | $128.00 |
| Danielle Brill | Raymond James | Announces | Outperform | $155.00 | - |
| Brian Abrahams | RBC Capital | Maintains | Sector Perform | $133.00 | $133.00 |
| Brian Abrahams | RBC Capital | Lowers | Sector Perform | $133.00 | $136.00 |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $155.00 | $155.00 |
| Carter Gould | Barclays | Lowers | Overweight | $160.00 | $180.00 |
| Charles Duncan | Cantor Fitzgerald | Lowers | Overweight | $155.00 | $170.00 |
| Evan Seigerman | BMO Capital | Lowers | Market Perform | $128.00 | $142.00 |
| David Amsellem | Piper Sandler | Raises | Overweight | $159.00 | $131.00 |
| Brian Abrahams | RBC Capital | Lowers | Sector Perform | $136.00 | $143.00 |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $190.00 | $190.00 |
| Akash Tewari | Jefferies | Raises | Buy | $189.00 | $177.00 |
| Anupam Rama | JP Morgan | Raises | Overweight | $181.00 | $173.00 |
| Andrew Fein | HC Wainwright & Co. | Raises | Buy | $190.00 | $160.00 |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $143.00 | $136.00 |
| Yatin Suneja | Guggenheim | Raises | Buy | $180.00 | $170.00 |
| David Hoang | Citigroup | Raises | Neutral | $158.00 | $150.00 |
| Jay Olson | Oppenheimer | Raises | Outperform | $219.00 | $216.00 |
| Carter Gould | Barclays | Raises | Overweight | $180.00 | $169.00 |
| Brian Skorney | Baird | Raises | Outperform | $180.00 | $157.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Neurocrine Biosciences. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Neurocrine Biosciences compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Neurocrine Biosciences's stock. This comparison reveals trends in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Neurocrine Biosciences's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Neurocrine Biosciences analyst ratings.
Get to Know Neurocrine Biosciences Better
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
Understanding the Numbers: Neurocrine Biosciences's Finances
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Neurocrine Biosciences's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 30.37%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Neurocrine Biosciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 11.01%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Neurocrine Biosciences's ROE stands out, surpassing industry averages. With an impressive ROE of 2.66%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Neurocrine Biosciences's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.92% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Neurocrine Biosciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.1.
Analyst Ratings: What Are They?
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
